Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Evelo Biosciences was a clinical-stage biotechnology company focused on developing orally-delivered, gut-restricted medicines, specifically monoclonal microbials, to act on the small intestinal axis (SINTAX) for the treatment of inflammatory diseases. The company aimed to discover and develop therapies that could address a broad range of immune-related conditions. Evelo Biosciences was founded by Flagship Pioneering. In October 2023, Evelo Biosciences filed for Chapter 7 bankruptcy and subsequently ceased all operations.
The Cambridge headquarters served as the central location for Evelo's research and development activities, clinical operations, and corporate administration before the company ceased operations.
The facility likely included advanced laboratory spaces for microbial candidate development and analysis, along with office areas designed for a biotech research environment. Its location in Cambridge offered proximity to leading academic institutions and other biotech companies.
As a clinical-stage biotechnology company, the work culture at Evelo Biosciences likely emphasized scientific innovation, collaboration, a fast-paced environment driven by research milestones, and a strong focus on translating scientific discoveries into potential therapies. This culture ceased with the company's dissolution.
The Cambridge headquarters was significant due to its strategic location within a leading global biotech ecosystem, providing access to talent, research collaborations, and venture capital. This environment was crucial for its R&D efforts.
Prior to ceasing operations, Evelo Biosciences was primarily based in the United States. Its global presence was mainly through its clinical trial activities, which may have involved sites and collaborations in various countries to test its investigational therapies. The company did not have significant physical office locations outside of its Cambridge, MA headquarters.
620 Memorial Dr, Suite 200W
Cambridge
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Evelo Biosciences' leadership includes:
Evelo Biosciences has been backed by several prominent investors over the years, including:
In the year leading up to its bankruptcy, Evelo Biosciences experienced key executive changes, notably in its CFO position. The Chapter 7 filing in October 2023 ultimately resulted in the departure of all remaining executives as the company ceased operations.
Discover the tools Evelo Biosciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Historically, Evelo Biosciences likely used common corporate email formats. Given the company has ceased operations, these email addresses are no longer active.
[first_initial][last]@evelobio.com (e.g., jdoe@evelobio.com) or [first].[last]@evelobio.com (e.g. jane.doe@evelobio.com)
Format
sgill@evelobio.com
Example
0%
Success rate
Endpoints News • October 27, 2023
Evelo Biosciences, a company developing therapies based on microbial CBMs, filed for Chapter 7 bankruptcy. This move signals liquidation of assets and cessation of operations....more
BioSpace • October 30, 2023
Evelo Biosciences has filed for Chapter 7 bankruptcy, indicating it will cease operations and liquidate its assets. The company had been working on oral biologics for inflammatory diseases....more
PR Newswire • June 12, 2023
Evelo Biosciences announced the appointment of Luca Scavo as its new Chief Financial Officer (CFO) and Chief Business Officer (CBO), effective June 12, 2023. He succeeded Marella Thorell who stepped down....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Evelo Biosciences, are just a search away.